Amy McMichael, MD Professor and Chair Department of Wake Forest Baptist Health Winston-Salem, NC SEC 2019 DISCLOSURE/CONFLICTS OF INTEREST

Investigator Consultant

Allergan Johnson & Johnson Intendis Procter & Gamble Procter & Gamble Stiefel Samumed Allergan Casseopia Bayer Concert Galderma Alcaris Incyte Incyte Samumed Aclaris Anacor Pfizer Nutrafol Bioniz 157 articles on “ loss and African Americans” in Pub Med from 1968 – 2019 99 articles on Central Centrifugal Cicatricial Alopecia 101 articles on Pseudofolliculitis barbae 349 Frontal fibrosing alopecia (225 articles in 2017) 4214 articles on >40,000 articles on psoriasis > 20,000 articles on atopic dermatitis TOP DIAGNOSES IN AFRICAN AMERICAN PATIENT VISITS TO DERMATOLOGISTS NATIONAL AMBULATORY MEDICAL CARE SURVEY 1993-2009 Diagnosis ICD-9 Code No. of Visits % of Visits 706.1 5,720,000 22.1% Unspec. dermatitis 692.9 3,640,000 14.0%

Seb dermatitis 690.10 1,990,000 7.7%

Atopic derm 691.8 1,590,000 6.1% Dyschromia 709.0 1,290,000 5.0% Psoriasis 696.1 950,000 3.6% Alopecia 704.00 920,000 3.6% Keloid 701.4 830,000 3.2% Viral warts 078.1 780,000 3.0% Sebaceous 706.2 780,000 3.0%

Davis SA, et al. J Drugs Dermatol 2012 TOP DIAGNOSES IN AFRICAN AMERICAN PATIENT VISITS TO DERMATOLOGISTS NATIONAL AMBULATORY MEDICAL CARE SURVEY 1993-2009 Diagnosis ICD-9 Code No. of Visits % of Visits Acne 706.1 5,720,000 22.1% Unspec. dermatitis 692.9 3,640,000 14.0%

Seb dermatitis 690.10 1,990,000 7.7%

Atopic derm 691.8 1,590,000 6.1% Dyschromia 709.0 1,290,000 5.0% Psoriasis 696.1 950,000 3.6% Alopecia 704.00 920,000 3.6% Keloid scar 701.4 830,000 3.2% Viral warts 078.1 780,000 3.0% 706.2 780,000 3.0%

Davis SA, et al. J Drugs Dermatol 2012 CENTRAL CENTRIFUGAL SCARRING ALOPECIA EPIDEMIOLOGY

▪ Prevalence ranges from 2.7% in 604 South African women to 5.6% in 529 US women1,2 ▪ Wide range of clinical severity ▪ Symptoms range from none to severe pruritus and pain ▪ Mostly women of African descent, ages 30-65 ▪ Often accompanied by ▪ Pre-dated chemical relaxers ▪ Traction common theme 1. Khumalo NP et al, BJD. 2007 2. Olsen EA et al, JAAD. 2011 3. Yolanda Lenzy, personal communication, AAD 2016 • Hopkins study of 447 women (0.09%) with a medical history of CCCA were identified, 62 of whom had uterine leiomyomas (ULs) • Women with CCCA have nearly 5 times increased odds of having uterine leiomyomas compared with race-, age-, and sex-matched controls - Dina et al, JAMA Dermatol 2017

• Microarray data from 5 CCCA patients suggesting upregulation of critical implicated in fibroproliferative disorders in the expression profile of patients with CCCA – Aguh et al, JAAD 2018 Central Alopecia Photographic Scale in African American Women

Olsen EA, Callender V, Sperling L, McMichael A, Anstrom KJ, Bergfeld W, Durden F, Roberts J, Shapiro J and Whiting DA— Derm Therapy Vol 21, 2008 ▪ 9 patients with vertex hair breakage ▪ 8/9 with biopsy results ▪ 5 showed typical CCCA changes ▪ 1 showed advanced end-stage scarring alopecia ▪ 2 showed premature desquamation of inner root sheath (suggestive of early CCCA) ▪ CallenderV, Wright D, Davis E, Sperling L Arch Dermatol 2012 Tosti and Miteva, Skin Appendage 2015 My patient  Dermatoscopic evaluation: can be followed with treatment

 Perifollicular scale and erythema activity  Significant loss of follicular openings burnt out disease  Miniaturization of hair shafts possible ability to recruit and have regrowth ▪ 10 women with bx-proven CCCA ▪ Clinical and dermatoscopic photographs obtained from clinically active alopecic site and clinically- unaffected posterior scalp ▪ All 10 patients with histologic changes of CCCA 4 cm below clinical changes ▪ Dermatoscopic findings suggest early changes of CCCA and correlate with path ▪ Dermoscopy may be reliable, less invasive option to visualize CCCA changes ▪ Early treatment in proximal areas may reduce disease severity and improve quality of life for CCCA patients

▪ Dlova et al, Autosomal dominant inheritance of central centrifugal cicatricial alopecia in black South Africans. JAAD, 2014;70:679-682 ▪ 14 index families with 31 immediate family members ▪ Pedigree analysis suggests autosomal

▪ Collaborative study with U.S. and S. African patients and Genetics group in Israel ▪ 16 patients, identified one splice site and three heterozygous missense mutations in PADI3 ▪ PADI3 encodes peptidyl arginine deiminase, type III (PADI3), an enzyme that post- translationally modifies other essential to hair-shaft formation ▪ shown in some cases to involve mutations in PADI3- (no alopecia) ▪ Mutations resulted in reduced PADI3 expression, abnormal intracellular localization of the , and decreased enzymatic activity ▪ Immunofluorescence staining showed decreased expression of PADI3 in biopsy samples of scalp skin from patients with CCCA ▪ Replication set of 42 patients was directly sequenced. Combining data sets, we found pathogenic variants in 14 out of 58 affected patients (24%). Liron Malki et al, New England Journal of Med, Feb 2019 Stained with anti-PADI3 specific antibodies ▪ Retrospective study of patients staged at beginning and end of treatment ▪ Treatment = IL Kenalog, topical steroids, +/- minoxidil ▪ N = 15 ▪ After treatment: ▪ 5/15 (33.3%) had decreased severity scores (Improved) ▪ 8/15 (53.3%) had increased severity scores (Worsened) ▪ 2/15 (13.3%) had no change in severity scores  Discuss Genetic predisposition with patients to increase awareness  +/- Biopsy for extent of /alternate diagnosis  Decrease all traumatic styling methods and heat behaviors to vertex scalp

 Inflammatory Stage ▪ Moisturizing anti-dandruff shampoos weekly ▪ Decrease inflammation via topical and intralesional corticosteroids ▪ IL Kenalog for 8 rounds with 5.0-7.5 mg/cc for max 3 cc/visit (q 6-8 weeks) ▪ Oral/topical for pustular disease ▪ Push treatment until symptom free

 Post-inflammatory treatment ▪ Long term topical steroids ▪ Minoxidil solution for prolongation of anagen ▪ Surgical restoration ▪ ?PRP  Discuss Genetic predisposition with patients to increase awareness  +/- Biopsy for extent of inflammation/alternate diagnosis  Decrease all traumatic styling methods and heat behaviors to vertex scalp  CARF – Cicatricial Alopecia Research Foundation  Skin of Color Society short film (www.skinofcolorsociety.org)

 Inflammatory Stage ▪ Moisturizing anti-dandruff shampoos weekly ▪ Decrease inflammation via topical and intralesional corticosteroids ▪ IL Kenalog for 8 rounds with 5.0-7.5 mg/cc for max 3 cc/visit (q 6-8 weeks) ▪ Oral/topical antibiotics for pustular disease ▪ Push treatment until symptom free

 Post-inflammatory treatment ▪ Long term topical steroids ▪ Minoxidil solution for prolongation of anagen ▪ Surgical restoration ▪ ?PRP ▪ Scarring alopecia difficult to treat ▪ Treatment often leads to disappointing outcomes for patients ▪ Idea is to rescue and recruit that are undecided in their fate ▪ Must rescue hairs that are under inflammatory attack but have not succumbed to fibrosis ▪ Stabilization may be the outcome but may see improved density

Pre-treatment Post-medical treatment Post-surgical treatment DINA Y, AGUH C. DERMATOL SURG. 2018 NIGERIAN WOMAN TREATMENT : IL KENALOG AND HAIR RESTORATION

Pretreatment Post-treatment

6 mo weave in 9 mo/treatment place

Pre-treatment 3 mo/treatment ▪ Use your dermatoscope to look for early disease ▪ Discuss known genetics with CCCA patients to encourage family members to share their experience ▪ Manage traction-related hair care practices ▪ Aggressively manage anti-inflammatory treatments ▪ In post-inflammatory stage, use minoxidil (off-label) and continue topical steroids ▪ Follow these patients yearly to ensure stable disease ▪ Refer for surgical restoration in appropriate cases THANK YOU FOR YOUR ATTENTION!

[email protected]

North American Hair Research Society www.nahrs.org Cicatricial Alopecia Research Foundation www.carfintl.org National Alopecia Areata Foundation www.naaf.org